{"id":"https://openalex.org/W7204462004","doi":"https://doi.org/10.1200/oa-25-00190","title":"Phase I Dose Escalation and Cohort Expansion of Lorigerlimab, a Bispecific PD-1 \u00d7 CTLA-4 DART Molecule With Focus on Metastatic Castration-Resistant Prostate Cancer","display_name":"Phase I Dose Escalation and Cohort Expansion of Lorigerlimab, a Bispecific PD-1 \u00d7 CTLA-4 DART Molecule With Focus on Metastatic Castration-Resistant Prostate Cancer","publication_year":2026,"publication_date":"2026-07-01","ids":{"openalex":"https://openalex.org/W7204462004","doi":"https://doi.org/10.1200/oa-25-00190"},"language":"en","primary_location":{"id":"doi:10.1200/oa-25-00190","doi":"https://doi.org/10.1200/oa-25-00190","is_oa":true,"landing_page_url":"https://doi.org/10.1200/oa-25-00190","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/OA-25-00190","source":{"id":"https://openalex.org/S4404662432","display_name":"JCO oncology advances.","issn_l":"2994-9750","issn":["2994-9750"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj"],"host_organization":"https://openalex.org/P4310315860","host_organization_name":"Wolters Kluwer Health","host_organization_lineage":["https://openalex.org/P4310315860","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer Health","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO Oncology Advances","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://ascopubs.org/doi/pdfdirect/10.1200/OA-25-00190","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063337705","display_name":"Jason J. Luke","orcid":"https://orcid.org/0000-0002-1182-4908","observed_orcids":["https://orcid.org/0000-0002-1182-4908"]},"institutions":[{"id":"https://openalex.org/I170201317","display_name":"University of Pittsburgh","ror":"https://ror.org/01an3r305","country_code":"US","type":"education","lineage":["https://openalex.org/I170201317"]},{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]},{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason J. Luke","raw_affiliation_strings":["UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA"],"raw_orcid":"https://orcid.org/0000-0002-1182-4908","affiliations":[{"raw_affiliation_string":"UPMC Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA","institution_ids":["https://openalex.org/I170201317","https://openalex.org/I4210128526","https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026102058","display_name":"Manish R. Sharma","orcid":"https://orcid.org/0009-0000-9769-0850","observed_orcids":["https://orcid.org/0009-0000-9769-0850"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Manish R. Sharma","raw_affiliation_strings":["START Center for Cancer Research\u2014Midwest, Grand Rapids, MI"],"raw_orcid":"https://orcid.org/0009-0000-9769-0850","affiliations":[{"raw_affiliation_string":"START Center for Cancer Research\u2014Midwest, Grand Rapids, MI","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110574746","display_name":"Sreenivasa Rao Chandana","orcid":"https://orcid.org/0000-0001-5390-9937","observed_orcids":["https://orcid.org/0000-0001-5390-9937"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sreenivasa R. Chandana","raw_affiliation_strings":["START Center for Cancer Research\u2014Midwest, Grand Rapids, MI"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"START Center for Cancer Research\u2014Midwest, Grand Rapids, MI","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5140922896","display_name":"Iwona Lugowska","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210150880","display_name":"The Maria Sklodowska-Curie National Research Institute of Oncology","ror":"https://ror.org/04qcjsm24","country_code":"PL","type":"healthcare","lineage":["https://openalex.org/I4210150880"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Iwona Lugowska","raw_affiliation_strings":["Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland","institution_ids":["https://openalex.org/I4210150880"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004376320","display_name":"Jakub \u017bo\u0142nierek","orcid":"https://orcid.org/0000-0003-2946-870X","observed_orcids":["https://orcid.org/0000-0003-2946-870X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jakub \u017bo\u0142nierek","raw_affiliation_strings":["Szamocka Hospital, LuxMed Oncology, Warsaw, Poland"],"raw_orcid":"https://orcid.org/0000-0003-2946-870X","affiliations":[{"raw_affiliation_string":"Szamocka Hospital, LuxMed Oncology, Warsaw, Poland","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5105923745","display_name":"Gregory Michael Cote","orcid":"https://orcid.org/0000-0003-0181-886X","observed_orcids":["https://orcid.org/0000-0003-0181-886X"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory M. Cote","raw_affiliation_strings":["Mass General Cancer Center, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0003-0181-886X","affiliations":[{"raw_affiliation_string":"Mass General Cancer Center, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030070924","display_name":"Charlene M. Mantia","orcid":"https://orcid.org/0000-0001-7672-3131","observed_orcids":["https://orcid.org/0000-0001-7672-3131"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charlene M. Mantia","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0001-7672-3131","affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054931755","display_name":"Rafa\u0142 Dziadziuszko","orcid":"https://orcid.org/0000-0001-8080-9843","observed_orcids":["https://orcid.org/0000-0001-8080-9843"]},"institutions":[{"id":"https://openalex.org/I75124487","display_name":"Gda\u0144sk Medical University","ror":"https://ror.org/019sbgd69","country_code":"PL","type":"education","lineage":["https://openalex.org/I75124487"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Rafal Dziadziuszko","raw_affiliation_strings":["Early Phase Clinical Trials Center, Medical University of Gda\u0144sk, Gda\u0144sk, Poland"],"raw_orcid":"https://orcid.org/0000-0001-8080-9843","affiliations":[{"raw_affiliation_string":"Early Phase Clinical Trials Center, Medical University of Gda\u0144sk, Gda\u0144sk, Poland","institution_ids":["https://openalex.org/I75124487"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005462156","display_name":"Rachel E. Sanborn","orcid":"https://orcid.org/0000-0003-0542-6054","observed_orcids":["https://orcid.org/0000-0003-0542-6054"]},"institutions":[{"id":"https://openalex.org/I2801670537","display_name":"Providence Portland Medical Center","ror":"https://ror.org/015tmw922","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801670537","https://openalex.org/I4210160466","https://openalex.org/I94396219"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel E. Sanborn","raw_affiliation_strings":["Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR"],"raw_orcid":"https://orcid.org/0000-0003-0542-6054","affiliations":[{"raw_affiliation_string":"Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR","institution_ids":["https://openalex.org/I2801670537"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001527986","display_name":"Amy E. Goodman","orcid":"https://orcid.org/0009-0003-8655-6260","observed_orcids":["https://orcid.org/0009-0003-8655-6260"]},"institutions":[{"id":"https://openalex.org/I4210128526","display_name":"UPMC Hillman Cancer Center","ror":"https://ror.org/03bw34a45","country_code":"US","type":"facility","lineage":["https://openalex.org/I170201317","https://openalex.org/I4210128526"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amy E. Goodman","raw_affiliation_strings":["UPMC Hillman Cancer Center, Pittsburgh, PA"],"raw_orcid":"https://orcid.org/0009-0003-8655-6260","affiliations":[{"raw_affiliation_string":"UPMC Hillman Cancer Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210128526"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048842300","display_name":"Francine Z. Chen","orcid":"https://orcid.org/0000-0003-4024-9620","observed_orcids":["https://orcid.org/0000-0003-4024-9620"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Francine Z. Chen","raw_affiliation_strings":["AbbVie, South San Francisco, CA","MacroGenics, Inc, Brisbane, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie, South San Francisco, CA","institution_ids":["https://openalex.org/I2948539688"]},{"raw_affiliation_string":"MacroGenics, Inc, Brisbane, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028719199","display_name":"Anushka De Costa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anushka De Costa","raw_affiliation_strings":["AbbVie, South San Francisco, CA","MacroGenics, Inc, Brisbane, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie, South San Francisco, CA","institution_ids":["https://openalex.org/I2948539688"]},{"raw_affiliation_string":"MacroGenics, Inc, Brisbane, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045680939","display_name":"Denise Casey","orcid":"https://orcid.org/0000-0002-6671-284X","observed_orcids":["https://orcid.org/0000-0002-6671-284X"]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Denise Casey","raw_affiliation_strings":["MacroGenics, Inc, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MacroGenics, Inc, Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032994967","display_name":"Tiziana Di Pucchio","orcid":"https://orcid.org/0000-0002-0217-0367","observed_orcids":["https://orcid.org/0000-0002-0217-0367"]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tiziana Di Pucchio","raw_affiliation_strings":["MacroGenics, Inc, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MacroGenics, Inc, Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101571126","display_name":"Jichao Sun","orcid":"https://orcid.org/0000-0003-2321-1858","observed_orcids":["https://orcid.org/0000-0003-2321-1858"]},"institutions":[{"id":"https://openalex.org/I4210106297","display_name":"MacroGenics (United States)","ror":"https://ror.org/01hcd4187","country_code":"US","type":"company","lineage":["https://openalex.org/I4210106297"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jichao Sun","raw_affiliation_strings":["MacroGenics, Inc, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MacroGenics, Inc, Rockville, MD","institution_ids":["https://openalex.org/I4210106297"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5088645894","display_name":"Bo\u017cena Cybulska-Stopa","orcid":"https://orcid.org/0000-0002-0975-850X","observed_orcids":["https://orcid.org/0000-0002-0975-850X"]},"institutions":[{"id":"https://openalex.org/I11923345","display_name":"Wroc\u0142aw University of Science and Technology","ror":"https://ror.org/008fyn775","country_code":"PL","type":"education","lineage":["https://openalex.org/I11923345"]},{"id":"https://openalex.org/I219388962","display_name":"University of Wroc\u0142aw","ror":"https://ror.org/00yae6e25","country_code":"PL","type":"education","lineage":["https://openalex.org/I219388962"]}],"countries":["PL"],"is_corresponding":false,"raw_author_name":"Bo\u017cena Cybulska-Stopa","raw_affiliation_strings":["Oncology Department, Lower Silesian Center for Oncology and Pulmonology and Hematology Department of Hematology and Oncology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroc\u0142aw, Poland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Department, Lower Silesian Center for Oncology and Pulmonology and Hematology Department of Hematology and Oncology, Faculty of Medicine, Wroclaw University of Science and Technology, Wroc\u0142aw, Poland","institution_ids":["https://openalex.org/I11923345","https://openalex.org/I219388962"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":12,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.61554936,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"3","issue":"3","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9746000170707703,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.023099999874830246,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.7820000052452087},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.8939999938011169},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.9990000128746033},{"id":"https://openalex.org/keywords/metastatic-castration-resistant-prostate-cancer","display_name":"metastatic castration-resistant prostate cancer","score":0.8899999856948853},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.7559999823570251},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.656000018119812},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.7229999899864197},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.9850000143051147},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.6100000143051147},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.984000027179718},{"id":"https://openalex.org/keywords/psa-response","display_name":"PSA response","score":0.7839999794960022},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6740000247955322},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7590000033378601},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.7509999871253967},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.8820000290870667}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7562000155448914},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.6859999895095825},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6262999773025513},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5853000283241272},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.580299973487854},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.4763999879360199},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4458000063896179},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.41670000553131104},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.413100004196167},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3995000123977661},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3865000009536743},{"id":"https://openalex.org/C188198153","wikidata":"https://www.wikidata.org/wiki/Q1613840","display_name":"Limiting","level":2,"score":0.38119998574256897},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.37860000133514404},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.3684999942779541},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3327000141143799},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.32580000162124634},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.30390000343322754},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2888000011444092},{"id":"https://openalex.org/C2776235491","wikidata":"https://www.wikidata.org/wiki/Q9625","display_name":"Prostate","level":3,"score":0.27730000019073486},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.2736000120639801},{"id":"https://openalex.org/C2781406297","wikidata":"https://www.wikidata.org/wiki/Q409450","display_name":"Prostate-specific antigen","level":4,"score":0.26840001344680786},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.26089999079704285},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.25839999318122864},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2572999894618988},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.25119999051094055}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/oa-25-00190","doi":"https://doi.org/10.1200/oa-25-00190","is_oa":true,"landing_page_url":"https://doi.org/10.1200/oa-25-00190","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/OA-25-00190","source":{"id":"https://openalex.org/S4404662432","display_name":"JCO oncology advances.","issn_l":"2994-9750","issn":["2994-9750"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj"],"host_organization":"https://openalex.org/P4310315860","host_organization_name":"Wolters Kluwer Health","host_organization_lineage":["https://openalex.org/P4310315860","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer Health","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO Oncology Advances","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1200/oa-25-00190","doi":"https://doi.org/10.1200/oa-25-00190","is_oa":true,"landing_page_url":"https://doi.org/10.1200/oa-25-00190","pdf_url":"https://ascopubs.org/doi/pdfdirect/10.1200/OA-25-00190","source":{"id":"https://openalex.org/S4404662432","display_name":"JCO oncology advances.","issn_l":"2994-9750","issn":["2994-9750"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj"],"host_organization":"https://openalex.org/P4310315860","host_organization_name":"Wolters Kluwer Health","host_organization_lineage":["https://openalex.org/P4310315860","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer Health","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JCO Oncology Advances","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9922999739646912,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7204462004.pdf","grobid_xml":"https://content.openalex.org/works/W7204462004.grobid-xml"},"referenced_works_count":38,"referenced_works":["https://openalex.org/W1488069418","https://openalex.org/W1516033866","https://openalex.org/W1979811833","https://openalex.org/W1981528932","https://openalex.org/W2012711310","https://openalex.org/W2019607817","https://openalex.org/W2102862705","https://openalex.org/W2103959341","https://openalex.org/W2143163879","https://openalex.org/W2166662937","https://openalex.org/W2273962363","https://openalex.org/W2330814896","https://openalex.org/W2531934133","https://openalex.org/W2568665052","https://openalex.org/W2976744492","https://openalex.org/W3043703771","https://openalex.org/W3049720236","https://openalex.org/W3083951977","https://openalex.org/W3115547163","https://openalex.org/W3138556548","https://openalex.org/W3141168022","https://openalex.org/W3159504492","https://openalex.org/W3176474008","https://openalex.org/W3178157575","https://openalex.org/W3202421829","https://openalex.org/W3206775306","https://openalex.org/W4205740972","https://openalex.org/W4220826761","https://openalex.org/W4220869779","https://openalex.org/W4308179948","https://openalex.org/W4372291446","https://openalex.org/W4376609743","https://openalex.org/W4386305289","https://openalex.org/W4387782335","https://openalex.org/W4387810032","https://openalex.org/W4388221248","https://openalex.org/W4390692472","https://openalex.org/W4391302547"],"related_works":["https://openalex.org/W4324136880","https://openalex.org/W4391302547","https://openalex.org/W2977890115","https://openalex.org/W3206647534","https://openalex.org/W4308381471","https://openalex.org/W2337805480","https://openalex.org/W2563849899","https://openalex.org/W3081413581","https://openalex.org/W2130846254","https://openalex.org/W3083951977"],"abstract_inverted_index":{"PURPOSE":[0],"Dual":[1],"blockade":[2],"of":[3,152,168,180,195,251],"PD-(L)1":[4],"and":[5,26,51,91,121,189,193,226,257,276,287],"cytotoxic":[6],"T-lymphocyte\u2013associated":[7],"protein-4":[8],"(CTLA-4)":[9],"increases":[10,19],"antitumor":[11,87,277],"activity":[12,278],"beyond":[13],"checkpoint":[14,218],"inhibitor":[15],"monotherapies,":[16],"but":[17],"substantially":[18],"toxicity,":[20],"limiting":[21],"potential":[22],"for":[23,103,270],"long-term":[24],"outcomes":[25],"combination":[27],"strategies.":[28],"Lorigerlimab":[29,264],"is":[30,301],"an":[31],"investigational":[32],"bispecific":[33],"PD-1":[34],"\u00d7":[35],"CTLA-4":[36,42],"DART":[37],"molecule":[38],"designed":[39],"to":[40,44,58],"enhance":[41],"binding":[43,54],"T":[45,261],"cells":[46],"in":[47,55,73,108,118,128,166,177,201,208,237,244,254,259,281,293,299],"the":[48,79,129,150,169,196,271],"tumor":[49],"microenvironment":[50],"limit":[52],"T-cell":[53],"normal":[56],"tissue":[57],"increase":[59],"tolerability.":[60],"METHODS":[61],"A":[62,295],"phase":[63,297],"I,":[64],"dose-escalation/cohort-expansion":[65],"study":[66],"(ClinicalTrials.gov":[67],"identifier:":[68],"NCT03761017":[69],")":[70],"evaluated":[71,94,127],"lorigerlimab":[72,142,148,202,296],"advanced":[74],"solid":[75],"tumors.":[76],"Safety":[77],"was":[78,106,113,126,239,279],"primary":[80],"end":[81,84],"point;":[82],"secondary":[83],"points":[85],"included":[86],"activity,":[88],"pharmacokinetics,":[89],"immunogenicity,":[90],"pharmacodynamics.":[92],"Doses":[93],"during":[95],"dose":[96,102],"escalation:":[97],"0.1-10.0":[98],"mg/kg.":[99],"The":[100,233],"recommended":[101],"expansion":[104,210,283],"(RDE)":[105],"investigated":[107],"four":[109],"cohorts.":[110],"Objective":[111,204,242],"response":[112,125,235,289],"assessed":[114],"per":[115],"RECIST":[116],"v1.1":[117],"all":[119,209,282],"cohorts,":[120],"prostate-specific":[122],"antigen":[123],"(PSA)":[124],"metastatic":[130],"castration-resistant":[131],"prostate":[132],"cancer":[133,223,230],"(mCRPC)":[134],"cohort.":[135],"RESULTS":[136],"Overall,":[137],"162":[138,170],"patients":[139,171,197],"received":[140,147],"\u22651":[141],"dose,":[143],"including":[144],"127":[145],"who":[146],"at":[149],"RDE":[151],"6":[153],"mg/kg":[154],"IV":[155],"once":[156],"every":[157],"3":[158],"weeks.":[159],"All-grade":[160],"treatment-related":[161],"adverse":[162,182],"event":[163],"(TRAEs)":[164],"occurred":[165],"85.8%":[167],"(139/162),":[172],"with":[173,248],"grade":[174],"\u22653":[175],"TRAEs":[176],"36.4%.":[178],"Rates":[179],"immune-related":[181],"events":[183],"(AEs)":[184],"were":[185,206,246,291],"34.6%":[186],"(all":[187],"grades)":[188],"13.4%":[190],"(grade":[191],"\u22653),":[192],"24.7%":[194],"experienced":[198],"AEs":[199],"resulting":[200],"discontinuation.":[203],"responses":[205,243],"observed":[207,280,292],"cohorts:":[211],"mCRPC":[212,238,245,300],"(25.0%,":[213],"9/36);":[214],"melanoma":[215],"(11.9%,":[216],"5/42);":[217],"na\u00efve":[219],"non\u2013small":[220],"cell":[221],"lung":[222],"(21.4%,":[224],"3/14);":[225],"microsatellite":[227],"stable":[228],"colorectal":[229],"(5.0%,":[231],"1/20).":[232],"PSA50":[234,288],"rate":[236],"28.6%":[240],"(12/42).":[241],"associated":[247],"increased":[249],"expression":[250],"inducible":[252],"costimulator":[253],"CD4":[255],"+":[256],"Ki67":[258],"circulating":[260],"cells.":[262],"CONCLUSION":[263],"demonstrated":[265],"a":[266],"manageable":[267],"safety":[268],"profile":[269],"dual":[272],"PD-(L)1/CTLA-4":[273],"targeting":[274],"strategy,":[275],"indications.":[284],"Durable":[285],"objective":[286],"rates":[290],"mCRPC.":[294],"II":[298],"ongoing.":[302]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2026-08-28T00:00:00"}